# Study of Activated CIK Armed With Bispecific Antibody for Advanced Liver Cancer

> **NCT03146637** · PHASE2 · UNKNOWN · sponsor: **Benhealth Biopharmaceutical (Shenzhen) Co., Ltd.** · enrollment: 80 (estimated)

## Conditions studied

- Advanced Liver Cancer

## Interventions

- **BIOLOGICAL:** Activated CIK
- **BIOLOGICAL:** CIK

## Key facts

- **NCT ID:** NCT03146637
- **Lead sponsor:** Benhealth Biopharmaceutical (Shenzhen) Co., Ltd.
- **Sponsor class:** INDUSTRY
- **Phase:** PHASE2
- **Study type:** INTERVENTIONAL
- **Status:** UNKNOWN
- **Start date:** 2017-05-01
- **Primary completion:** 2021-01-27
- **Final completion:** 2021-01-28
- **Target enrollment:** 80 (ESTIMATED)
- **Last updated:** 2021-02-01

## Collaborators

- [object Object]

## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT03146637

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT03146637, "Study of Activated CIK Armed With Bispecific Antibody for Advanced Liver Cancer". Retrieved via AI Analytics 2026-05-28 from https://api.ai-analytics.org/clinical/NCT03146637. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*